Biomet Spine Announces Open Sales Distribution Opportunities Nationwide for the SpF® Implantable Spine
Fusion Stimulator Product Family
Biomet WARSAW, Indiana ? Biomet, Inc. announced today that Biomet Spine, the company’s strategic business unit
concentrating on spine systems, has made a strategic business decision to accept applications from independent
contractor spine sales representatives throughout the United States to represent the SpF® Implantable Spine Fusion
Stimulator product family.
“This represents a tremendous opportunity for Biomet Spine and independent contractor spine sales representatives
nationwide,” said Glen Kashuba, President of Biomet Spine & Bone Healing Technologies. “The SpF® Stimulator product
family includes two product offerings – The SpF® PLUS?Mini Implantable Spinal Fusion Stimulator, which is indicated as a
posterolateral lumbar spine fusion adjunct for one or two levels, and the SpF® XL llb Implantable Spinal Fusion Stimulator,
which is indicated as a posterolateral lumbar spine fusion adjunct for three or more levels. With more than 100,000 SpF®
Stimulators implanted to date, the SpF® Stimulator product family has been a strong brand for us and we expect this trend
to continue far into the future.”
“This is truly an exciting opportunity for independent contractor spine sales representatives. We have a considerable
number of territories in which independent contractor sales representatives are eligible to represent SpF® Stimulators,”
said Mark Valentine, Senior Vice President of Sales and Marketing at Biomet Spine & Bone Healing Technologies. “The
SpF® Stimulator is widely recognized to be safe, economical and has a proven track record. With respect to product safety,
the SpF® Stimulator product family was commercialized in 1987 and has a history of minimal adverse effects. While
biologic products incur a cost for every fused level, the SpF® Stimulator requires only one flat device cost for one, two,
three or more levels, making it an economical solution. Backed by ample published papers, SpF® Stimulators feature a
proven technology, which has helped surgeons and patients for nearly 25 years.”
If you are a patient, Healthcare Professional or Healthcare Administrator who would like to learn more about SpF®
Implantable Spine Fusion Stimulators, please visit www.spfstimulator.com.
If you are an interested, prospective independent contractor sales representative who would like to learn more about
SpF® Stimulators and how to apply to distribute SpF® Implantable Spine Fusion Stimulators, please visit www.sellspf.com.
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal
medical specialists in both surgical and non?surgical therapy. Biomet’s product portfolio encompasses
reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and
dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and
external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal
products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as
arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its
subsidiaries currently distribute products in more than 100 countries.
This press release contains certain statements that are “forward?looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended.
Such statements are qualified by the inherent risks and uncertainties surrounding future expectations
generally, and also may materially differ from actual future experience involving any one or more of such
statements. Such risks and uncertainties include our ability to develop and market new products and
technologies in a timely manner, the effect of the pending merger on Biomet’s business and its relationship
with customers, distributors, employees and suppliers and the risk factors as set forth from time to time in
Biomet’s filings with the SEC. The inclusion of a forward?looking statement herein should not be regarded as a
representation by Biomet that Biomet’s objectives will be achieved. Biomet undertakes no obligation to
publicly update forward?looking statements, whether as a result of new information, future events or
otherwise.INDICATIONS: The SpF
PLUS?Mini (60µA/W) & SpF
PLUS?Mini (60µA/M) Implantable Fusion Stimulators are indicated as a spinal fusion adjunct to increase
the probability of fusion success in one or two (1 or 2) levels ? P850035/S031/033. The SpF
?XL IIb Implantable Spinal Fusion Stimulators are indicated as a
spinal fusion adjunct to increase the probability of fusion success in three (3) or more levels ? P850035/S023.
USAGE: All SpF
Implantable Spinal Fusion Stimulators have only been studied as an adjunct for lumbar spinal surgery i.e., posterolateral fusion. The
stimulators are designed for implantation for a period of approximately 24?weeks, assuming implantation occurs prior to the expiration “use before” date.
Federal Law (U.S.A.) restricts this device to sale by or on the order of a physician. Rx Only ? Prescription Only ? Single Use Only ? Do Not Reuse.
CONTRAINDICATIONS: There are no known contraindications regarding the use of SpF
Implantable Spinal Fusion Stimulators.
Warnings and precautions associated with the SpF® Implantable Spine Fusion Stimulator may be found online at biomet.com/stimmanuals or by calling
All trademarks are the property of Biomet, Inc. or one of its subsidiaries unless otherwise indicated. Rx Only.